News

Under the terms of the financing agreement, Aeolus received $1.5 million in gross proceeds in exchange for 5.35 million shares of Aeolus Pharmaceuticals common stock, and five year

This extends Idaho Technology’s ongoing program to license its intellectual property portfolio in cooperation with Roche Diagnostics. The agreement follows a series of intellectual property licensing agreements with

Caphosol is also indicated for hyposalivation and xerostomia irrespective of the cause. Bryan Morton, president and CEO of Eusa Pharma, said: “Caphosol’s introduction into the key French, German,

Infinity Pharmaceuticals has initiated a Phase II clinical trial of IPI-504, its lead heat shock protein 90 inhibitor, in combination with Herceptin in patients with human epidermal growth

The Osny business provides current good manufacturing practices development and manufacturing services for hormonal and other high potent drugs in oral dose forms that are either approved for

Dyax has received a complete response letter from the FDA pertaining to the company’s biologic license application for DX-88 for the treatment of acute attacks of hereditary angioedema.

The acquisition was completed on March 30, 2009 through the merger of JLL’s acquisition subsidiary, PDGI Acquisition (purchaser), with and into PharmaNet. As a result of the merger,

The joint venture will develop and commercialize Novavax’s seasonal influenza virus-like-particle (VLP)-based vaccine candidate and Cadila’s therapeutic vaccine candidates against cancer as well as its adjuvants, biogeneric and

Atritech, a US-based medical device company, has completed a $30m round of financing. Thomas, McNerney & Partners led the round along with a substantial investment from Split Rock